Ocular Therapeutix Inc
General ticker "OCUL" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $1.5B
Ocular Therapeutix Inc follows the US Stock Market performance with the rate: 54.0%.
Estimated limits based on current volatility of 2.6%: low 8.29$, high 8.73$
Factors to consider:
- Current price 62.2% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [2.08$, 5.28$]
- 2024-12-30 to 2025-12-30 estimated range: [2.54$, 6.03$]
Financial Metrics affecting the OCUL estimates:
- Negative: Non-GAAP EPS, $ of -1.37 <= 0.10
- Negative: Operating profit margin, % of -58.50 <= 1.03
- Negative: Operating cash flow per share per price, % of -20.18 <= 2.35
- Negative: negative Net income
Short-term OCUL quotes
Long-term OCUL plot with estimates
Financial data
| YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
|---|---|---|---|
| Operating Revenue | $43.52MM | $51.49MM | $58.44MM |
| Operating Expenses | $121.56MM | $130.15MM | $140.82MM |
| Operating Income | $-78.04MM | $-78.65MM | $-82.38MM |
| Non-Operating Income | $71.48MM | $7.62MM | $1.65MM |
| Interest Expense | $6.67MM | $7.02MM | $11.34MM |
| R&D Expense | $50.08MM | $53.46MM | $61.05MM |
| Income(Loss) | $-6.55MM | $-71.04MM | $-80.74MM |
| Profit(Loss) | $-6.55MM | $-71.04MM | $-80.74MM |
| Stockholders Equity | $88.00MM | $35.38MM | $91.13MM |
| Inventory | $1.25MM | $1.97MM | $2.31MM |
| Assets | $204.89MM | $149.29MM | $252.06MM |
| Operating Cash Flow | $-65.55MM | $-59.60MM | $-70.23MM |
| Capital expenditure | $1.19MM | $3.71MM | $6.09MM |
| Investing Cash Flow | $-1.19MM | $-3.71MM | $-6.09MM |
| Financing Cash Flow | $2.85MM | $1.45MM | $169.83MM |
| Earnings Per Share* | $-0.14 | $-0.83 | $-1.09 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.